Sarepta Therapeutics Inc (NASDAQ: SRPT) shares jumped up over 17 percent during Wednesday’s after-hours trading sessions, after the medical research and drug development company crushed earnings estimates.

A Closer Look At Q2 Earnings

Revenue: $35 million (consensus estimate was $22.3 million)

Adjusted Losses: $0.46 per share (was $1.19 per share last year)

Guidance: Raised to $125 million–$130 million (was $95 million)

After Nomura managing director Christopher Marai spoke to new CEO Doug Ingram following the earnings call, he also highlighted a positive view on Sarepta’s future similar to Ingram’s March 1 invitation theses. Marai maintains his Buy rating and set an $84 price target.

According to TipRanks, eight analysts are averaging a strong buy rating and a price target of $66 on Sarepta. Shares of Sarepta were trading at $40.20 during Thursday’s pre-market session, and at time of publication, shares were up 21.01 percent at $41.24.